Lung and bone metastases patterns in osteosarcoma: Chemotherapy improves overall survival
- PMID: 36705375
- PMCID: PMC9875956
- DOI: 10.1097/MD.0000000000032692
Lung and bone metastases patterns in osteosarcoma: Chemotherapy improves overall survival
Abstract
Osteosarcoma (OS) is a malignant tumor originating from the mesenchymal tissue. Simultaneous reports of lung and bone metastases (BM) in OS are rare in the literature. A total of 353 new cases of lung metastases (LM), 93 new cases of BM, and 59 new cases of LM and BM were diagnosed in the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2019. Univariate and multivariate logistic regression analyses were used to identify risk factors for LM and/or BM, and Cox regression analyses were performed to identify the prognostic factors for LM and/or BM. Kaplan-Meier (K-M) curves and log-rank tests were used to analyze the overall survival of patients with LM and/or BM. LM was diagnosed in 353 patients. Female sex, tumor size >100 mm, telangiectatic OS type, central OS type, N1 stage, other locations, BM, surgical treatments, radiotherapy and chemotherapy were significantly correlated with LM. 93 patients were diagnosed with BM. 25 to 59 years old, T1 stage, presence of LM, liver metastases, radiotherapy, and surgical treatments were significantly correlated with the BM. 59 patients were diagnosed with LM and BM. The chondroblastic OS type, small cell OS type, T1 stage, N1 stage, other locations, liver metastases, radiotherapy, and surgical treatments were significantly correlated with LM and BM. Metastases, radiotherapy, and surgery at the primary site were significantly associated with LM and/or BM. Chemotherapy at the primary site has been shown to be effective in improving the survival rate of LM and/or BM. Of the OS patients with LM, 61.47% died, and older age, BM, no surgery, and no chemotherapy were harmful to survival. 72.04% of OS patients with BM died, and N1 stage, no surgery, and no chemotherapy were harmful for survival. 69.49% of OS patients with LM and BM died, and older age and no chemotherapy were harmful for survival.
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures

Similar articles
-
Lung and bone metastases patterns in limb osteosarcoma: Surgical treatment of primary site improves overall survival.Medicine (Baltimore). 2023 Oct 20;102(42):e35671. doi: 10.1097/MD.0000000000035671. Medicine (Baltimore). 2023. PMID: 37861481 Free PMC article.
-
Lung and bone metastases patterns in Ewing sarcoma: Chemotherapy improves overall survival.Medicine (Baltimore). 2024 Sep 6;103(36):e39546. doi: 10.1097/MD.0000000000039546. Medicine (Baltimore). 2024. PMID: 39252261 Free PMC article.
-
Lung metastases pattern in limb osteosarcoma: A population-based study from 2010 to 2018.Medicine (Baltimore). 2022 Nov 11;101(45):e31212. doi: 10.1097/MD.0000000000031212. Medicine (Baltimore). 2022. PMID: 36397344 Free PMC article.
-
The role of radiotherapy in oseosarcoma.Cancer Treat Res. 2009;152:147-64. doi: 10.1007/978-1-4419-0284-9_7. Cancer Treat Res. 2009. PMID: 20213389 Review.
-
Pediatric Osteosarcoma: An Updated Review.Indian J Med Paediatr Oncol. 2017 Jan-Mar;38(1):33-43. doi: 10.4103/0971-5851.203513. Indian J Med Paediatr Oncol. 2017. PMID: 28469335 Free PMC article. Review.
Cited by
-
MTF2 facilitates the advancement of osteosarcoma through mediating EZH2/SFRP1/Wnt signaling.J Orthop Surg Res. 2024 Aug 8;19(1):467. doi: 10.1186/s13018-024-04965-9. J Orthop Surg Res. 2024. PMID: 39118123 Free PMC article.
-
The Use of Hydrogels for the Treatment of Bone Osteosarcoma via Localized Drug-Delivery and Tissue Regeneration: A Narrative Review.Gels. 2023 Mar 25;9(4):274. doi: 10.3390/gels9040274. Gels. 2023. PMID: 37102886 Free PMC article. Review.
-
Exploring the frontiers: The potential and challenges of bioactive scaffolds in osteosarcoma treatment and bone regeneration.Mater Today Bio. 2024 Sep 29;29:101276. doi: 10.1016/j.mtbio.2024.101276. eCollection 2024 Dec. Mater Today Bio. 2024. PMID: 39444939 Free PMC article. Review.
-
Using β-Elemene to reduce stemness and drug resistance in osteosarcoma: A focus on the AKT/FOXO1 signaling pathway and immune modulation.J Bone Oncol. 2024 Dec 19;50:100655. doi: 10.1016/j.jbo.2024.100655. eCollection 2025 Feb. J Bone Oncol. 2024. PMID: 39850453 Free PMC article.
References
-
- Kelleher FC, Cain JE, Healy JM, et al. . Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther. 2012;136:153–68. - PubMed
-
- Zhang L, Akiyama T, Fukushima T, et al. . Surgical resection of the primary lesion for osteosarcoma patients with metastasis at initial diagnosis. Jpn J Clin Oncol. 2021;51:416–23. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical